US selects first 10 drugs subject to Medicare price negotiations

The Centers for Medicare and Medicaid Services on Tuesday morning unveiled the first 10 drugs subject to price negotiations under the Inflation Reduction Act.

The list (in order) includes:

  • Bristol Myers Squibb’s Eliquis
  • Lilly’s Jardiance
  • Johnson & Johnson’s Xarelto
  • Merck’s Januvia
  • AstraZeneca’s Farxiga
  • Novartis’ Entresto

  • Click here to view original post